UBS Group
KLRS

UBS Group’s Kalaris Therapeutics KLRS Stock Holding History

UBS Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
262,131
+255,947
+4,139% +$1.33M ﹤0.01% 5679
2026
Q1 		$35.7K Buy
6,184
+3,493
+130% +$31K ﹤0.01% 7588
2025
Q4 		$22.7K Sell
2,691
-2,561
-49% -$16.4K ﹤0.01% 7694
2025
Q3 		$30.4K Buy
5,252
+1,136
+28% +$3.75K ﹤0.01% 7889
2025
Q2 		$11K Sell
4,116
-5,145
-56% -$23.2K ﹤0.01% 8806
2025
Q1 		$74.4K Buy
9,261
+3,804
+70% +$37.2K ﹤0.01% 7276
2024
Q4 		$52.7K Buy
5,457
+5,360
+5,526% +$81.1K ﹤0.01% 7263
2024
Q3 		$1.8K Sell
97
-1,524
-94% -$26.7K ﹤0.01% 8549
2024
Q2 		$27K Sell
1,621
-792
-33% -$14K ﹤0.01% 7119
2024
Q1 		$41.9K Sell
2,413
-223
-8% -$3.64K ﹤0.01% 6591
2023
Q4 		$41.2K Buy
2,636
+1,060
+67% +$41.8K ﹤0.01% 6657
2023
Q3 		$78K Buy
1,576
+1,223
+346% +$83.3K ﹤0.01% 5999
2023
Q2 		$27.6K Sell
353
-349
-50% -$33.2K ﹤0.01% 6749
2023
Q1 		$63.6K Sell
702
-121
-15% -$15.4K ﹤0.01% 6266
2022
Q4 		$97.1K Buy
823
+787
+2,186% +$133K ﹤0.01% 6130
2022
Q3 		$6K Sell
36
-9
-20% -$1.4K ﹤0.01% 9086
2022
Q2 		$4K Hold
45
– – ﹤0.01% 9158
2022
Q1 		$7K Sell
45
-2,733
-98% -$545K ﹤0.01% 8857
2021
Q4 		$827K Buy
2,778
+863
+45% +$400K ﹤0.01% 4551
2021
Q3 		$1.1M Buy
1,915
+1,129
+144% +$523K ﹤0.01% 4113
2021
Q2 		$357K Sell
786
-2,337
-75% -$1.21M ﹤0.01% 4963
2021
Q1 		$1.68M Buy
3,123
+3,111
+25,925% +$2.61M ﹤0.01% 3749
2020
Q4 		$11K Sell
12
-32
-73% -$24.6K ﹤0.01% 7436
2020
Q3 		$28K Buy
+44
New +$30K ﹤0.01% 6049

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

UBS Group's KLRS Position: Q2 2026 in Review

UBS Group increased its Kalaris Therapeutics (KLRS) stake by 4,139% in Q2 2026, buying an estimated $1.33M and bringing the position to 262,131 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5679.

UBS Group first reported a position in KLRS in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.68M in Q1 2021. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • UBS Group held 262,131 shares of Kalaris Therapeutics worth $1.07M as of Q2 2026.
  • UBS Group bought 255,947 Kalaris Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Kalaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5679 holding.
  • UBS Group first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • UBS Group's Kalaris Therapeutics position peaked at $1.68M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.